Objective To evaluate the efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (AECOPD).Methods We searched PubMed, EMBASE, and the Web of Science for relevant studies.Two reviewers extracted data and reviewed the quality of the studies independently.The primary outcome was clinical success at early follow-up.Study-level data were pooled using a random-effects model when I2 was >50% or a fixed-effects model when I2 was <50%.